R&D History
2020
2022 Bukwang Pharmaceutical submitted new drug application (NDA) of Lurasidone which is treatment for schizophrenia and bipolar depression
2022 Contera Pharma A/S, a subsidiary of Bukwang Pharm, develops new technology platform called ‘NOVA’ for people suffering from neurological disorders
2022 Contera Pharma A/S, a subsidiary of Bukwang Pharm, signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal
symptoms and morning akinesia in Parkinson´s disease
2022 Dyna therapeutics, a subsidiary of Bukwang Pharm, announces patent registration of SOL-804 in 32 countries
2022 Bukwang Pharmaceutical succeeds in phase 3 clinical trial for schizophrenia treatment, ‘Lurasidone’
2022 Dyna therapeutics, a subsidiary of Bukwang Pharm, announces completion of phase 1 of SOL-804 for Treatment of prostate cancer by KFDA
2021 Dyna therapeutics, a subsidiary of Bukwang Pharm, announces to register U.S. patent for "SOL-804," a candidate substance for anticancer drugs
2021 Dyna therapeutics, a subsidiary of Bukwang Pharm, Announces IND Approval of SOL-804 for treatment of prostate cancer by KFDA
2021 Contera Pharma A/S, a subsidiary of Bukwang Pharm, and abzu partner to design RNA therapeutics for rare diseases using xAI technology
2021 Contera Pharma A/S, a subsidiary of Bukwang Pharm, receives authorization from FDA to Initiate its phase 2 study of JM-010
2021 Dyna therapeutics, a subsidiary of Bukwang Pharm,’s anticancer drug candidate "SOL-804", patent registration completed in Europe, Australia, and Mexico
2020 Dyna therapeutics, a subsidiary of Bukwang Pharm,'s anticancer drug candidate "SOL-804", patent registration completed in Japan
2020 Bukwang Pharmaceutical exported the sedative, ‘Midazolam’ to Europe for the treatment of COVID-19
2020 Contera Pharma A/S, a subsidiary of Bukwang Pharm, receives US FDA approval for JM-010 phase 2 clinical study IND
2020 Contera Pharma A/S, a subsidiary of Bukwang Pharm, initiates dosing of JM-010 in Europe phase 2 study
2010
2019 University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease
2019 Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
2018 Bukwang Announces completion of dosing of MLR-1023’s phase 2b study.
2018 Bukwang initiates phase 3 study with lurasidone HCl for patients with Schizophrenia
2018 Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-induced dyskinesia in Parkinson’s disease. - International
application and registration of patents on therapeutic use and composition, formulations and metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.
2017 MLR-1023, a novel type 2 diabetic drug candidate, global Phase 2b subject enrollment has initiated
2017 JM-010, a treatment of dyskinesia in PD patients, received orphan drug designation from Korea MFDS
2017 Signed an Korea exclusive license agreement of lurasidone HCl, new drug for schizophrenia, with Sumitomo Dainippon Pharma
2016 Bukwang has entered a distribution deal with Kalbe International Pte. Ltd. to export "Dexid Tab" to six countires, including Philippines and Vietnam.
2016 Anticancer agent Apatinib Mesylate designated orphan drug from Korea MFDS
2015 Phase 2a study of anti-diabetic agent MLR-1023 and Phase 2 study of LID (levodopa-induced dyskinesia) candidate JM-010 each completed
2014 Acquired 100% shares of Danish biotech Contera Pharma
2014 Signed license agreement on JM-010, a candidate for movement disorder in Parkinson’s disease
2013 Acquired approval in Korea for Dexid Tab 480mg (R-thioctic acid tromethamine salt), R-form thioctic acid developed independently by Bukwang
2013 Signed license agreement on MLR-1023, an anti-diabetic candidate
2000
2009 Signed license agreement on YN968D1 (apatinib mesylate), an anti-cancer candidate and VEGFR inhibitor
2009 Acquired approval in Korea for Lonasen Tab. 2mg and 4mg, new drugs for schizophrenia developed by Sumitomo Dainippon Pharma in Japan
2007 Acquired approval in Korea for Nadixa Cream (nadifloxacin), new anti-acne drug developed by Ferrer in Spain
2006 Acquired approval in Korea for Levovir Cap. 30mg (clevudine), the 11th new drug in Korea and a new drug developed by Bukwang
2004 Acquired approval in Korea for Somazina Tab. 500mg (citicoline), a new drug for stroke developed by Ferrer in Spain
2002 Acquired approval in Korea for Thioctacid HR Tab. 600mg and 200mg, new drug for diabetic neuropathy, developed by Meda in Sweden
2001 Acquired approval in Korea for Asima Tab. (doxofylline), a new drug for COPD and asthma, developed by Eurodrug in Ireland
2000 Acquired approval in Korea for Ixel Cap. 50mg and 25mg (milnacipran HCl), a new anti-depressant developed by Pierre Fabre in France
1990
1998 Acquired approval in Korea for Thioctacid Tab. 200mg (thioctic acid), a new drug for diabetic neuropathy
1998 Acquired approval in Korea for Legalon Cap. 140 (Carduus marianus extract powder), a new drug for liver diseases
1995 Acquired approval in Korea for Navelbine Inj. (vinorelbine tartrate), a new anti-cancer drug for non-small cell lung cancer and progressive breast cancer
1990 Acquired approval in Korea for Bukwang Azeptin Tab. (azelastine HCl), a new drug for allergic rhinitis
1990 Acquired approval in Korea for Orfiril SR Tab. 300mg (sodium valproate), a new drug for epilepsy and mania
1980
1986 Acquired approval in Korea for Bukwang Kerlone Tab. (betaxolol HCl), a new beta-blocker for high blood pressure developed by Sanofi-Aventis in France
1970
1978 Acquired approval in Korea for Primalan Tab. (mequitazine), a new drug for rash and allergic rhinitis
1974 Acquired approval in Korea for Synthyroid Tab. 0.1mg (levothyroxine sodium hydrate), a new drug for hypothyroidism